In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Trump’s tariffs put copper market in the hot seat; Iron ore still a defensive play, but risks loom; How all this could impact ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The latest data from the Federal Reserve indicates that households of Americans aged 55 to 64 have a median of $185,000 in ...

“DM1 is a devastating disease with no approved therapies, and we are driven to deliver DYNE-101, a potentially transformative medicine, to patients as quickly as possible.” The FDA grants Fast Track ...

At a median follow-up of 8.4 years, T-DM1 improved both invasive disease-free survival and overall survival. The trial (NCT01772472) included 1486 patients with HER2-positive early breast cancer ...

T HURSDAY, Jan. 16, 2025 (HealthDay News) -- For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall ...

According to Geyer, an important finding was the consistent benefit of T-DM1 across patient subgroups. The analysis showed an approximately 50% reduction in risk of death and invasive disease ...